• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Mylan Inc.

NASDAQ:MYL

$21.63 $0.35 (1.64%)

REAL-TIME: Last trade at

Jump to this page for:

Related Resources

Mylan Launches Bonviva Generic - Analyst Blog

5/25/2012 by Nasdaq

Johnson & Johnson Setback Is Positive for Pfizer, Bristol-Myers

5/24/2012 by Minyanville

Shire Presents Data on Venvanse - Analyst Blog

5/24/2012 by Nasdaq

More Generic Launches for Mylan - Analyst Blog

5/24/2012 by Nasdaq

CEO Pay: Finally Worth It?

5/23/2012 by DailyFinance

WCRX, Watson Pharma in Legal Tussle - Analyst Blog

5/23/2012 by Nasdaq

The Zacks Analyst Blog Highlights: Mylan, Bristol-Myers Squibb, Sanofi, Teva Pharmaceuticals and Dr.

5/22/2012 by Nasdaq

Generic Launches Continue at Mylan - Analyst Blog

5/21/2012 by Nasdaq

FDA Approves Generic Versions Of Blood Thinning Drug Plavix

5/17/2012 by Smart Money

UPDATE:FDA Approves Generic Versions Of Blood-Thinning Drug Plavix

5/17/2012 by Smart Money

Mylan Raises 2012 Earnings Guidance - Analyst Blog

5/11/2012 by Nasdaq

This Just In: Upgrades and Downgrades

5/11/2012 by DailyFinance

Warner Chilcott Tops But Cuts View - Analyst Blog

5/7/2012 by Nasdaq

Best of the Blogs, Biotech: How Much Money Do the Top Pharma CEOs Make?

5/3/2012 by Minyanville

Stocks to watch Monday: Haemonetics, Merck

4/30/2012 by MarketWatch

2nd UPDATE: Warner Chilcott Confirms Strategic Review; In Talks With Potential Suitors

4/30/2012 by Smart Money

Mylan Beats Analyst Estimates on EPS

4/27/2012 by DailyFinance

US Judge Upholds Validity Of Merck's Vytorin Patent

4/27/2012 by Smart Money

UPDATE: US Judge Upholds Validity Of Merck's Vytorin Patent

4/27/2012 by Smart Money

Mylan 1Q Profit Rises 24%; EpiPen Settlement Reached With Teva

4/26/2012 by Smart Money

TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks

4/26/2012 by Smart Money

Stocks to watch Thursday: Watson, Teradyne, Crocs

4/26/2012 by MarketWatch

How High Can Pfizer Fly?

4/26/2012 by DailyFinance

Mylan Beats, Reaffirms Outlook - Analyst Blog

4/26/2012 by Nasdaq

Celgene Misses, Reaffirms - Analyst Blog

4/26/2012 by Nasdaq

TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks

4/25/2012 by Smart Money

Earnings Preview: Celgene - Analyst Blog

4/24/2012 by Nasdaq

Yet Another Delay for Forest Labs - Analyst Blog

4/24/2012 by Nasdaq

U.S. stock gains hinge on Apple, blue-chip results

4/21/2012 by MarketWatch

MARKET SNAPSHOT: U.S. Stock Gains Hinge On Apple, Blue-chip Results

4/21/2012 by Smart Money

Forest Hit by Lexapro Generics - Analyst Blog

4/17/2012 by Nasdaq

Is Teva About to Tear Itself Apart?

4/13/2012 by DailyFinance

Forest Buys Bystolic Rights - Analyst Blog

4/9/2012 by Nasdaq

Has Mylan Become the Perfect Stock?

4/5/2012 by DailyFinance

Mylan Seeks To Overturn FDA's Provigil Decision

4/5/2012 by Smart Money

Teva Active on the Generics Front - Analyst Blog

4/5/2012 by Nasdaq

The Zacks Analyst Blog Highlights: AstraZeneca plc, Mylan, Teva Pharmaceuticals, Dr Reddy's Laborato

4/3/2012 by Nasdaq

The Zacks Analyst Blog Highlights: AstraZeneca, Teva Pharmaceuticals, Mylan, Dr Reddy's Laboratories

4/2/2012 by Nasdaq

AZN Drug Gets Positive Ruling in US - Analyst Blog

4/2/2012 by Nasdaq

Delay in Forest Drug FDA Action Date - Analyst Blog

3/30/2012 by Nasdaq
See More Articles...